Conventional chemotherapeutic approaches to treating tumours can be hit-and-miss. One way to ensure successful treatment may be to go for the jugular of cancer-cell survival signalling as well.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Wendel, H. -G. et al. Nature 428, 332–337 (2004).
Vivanco, I. & Sawyers, C. L. Nature Rev. Cancer 2, 489–501 (2002).
Basu, S., Totty, N. F., Irwin, M. S., Sudol, M. & Downward, J. Mol. Cell 11, 11–23 (2003).
Manning, B. D. & Cantley, L. C. Trends Biochem. Sci. 28, 573–576 (2003).
Neshat, M. S. et al. Proc. Natl Acad. Sci. USA 98, 10314–10319 (2001).
Lin, T. A. et al. Science 266, 653–656 (1994).
Pause, A. et al. Nature 371, 762–767 (1994).
Li, S. et al. J. Biol. Chem. 278, 3015–3022 (2003).
Topisirovic, I. et al. Mol. Cell. Biol. 23, 8992–9002 (2003).
Rights and permissions
About this article
Cite this article
McCormick, F. Survival pathways meet their end. Nature 428, 267–269 (2004). https://doi.org/10.1038/428267a
This article is cited by
Rapamycin Protects Spiral Ganglion Neurons from Gentamicin-Induced Degeneration In Vitro
Journal of the Association for Research in Otolaryngology (2019)
Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas
Journal of Neuro-Oncology (2011)